[HTML][HTML] Characterization of sigma 1 receptor antagonist CM-304 and its analog, AZ-66: novel therapeutics against allodynia and induced pain
TJ Cirino, SO Eans, JM Medina, LL Wilson… - Frontiers in …, 2019 - frontiersin.org
Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception without
the liabilities of opioids, offering a promising therapeutic target to treat pain. The purpose of …
the liabilities of opioids, offering a promising therapeutic target to treat pain. The purpose of …
[HTML][HTML] Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
TJ Cirino, SO Eans, JM Medina, LL Wilson… - Frontiers in …, 2019 - ncbi.nlm.nih.gov
Abstract Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception
without the liabilities of opioids, offering a promising therapeutic target to treat pain. The …
without the liabilities of opioids, offering a promising therapeutic target to treat pain. The …
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain.
TJ Cirino, SO Eans, JM Medina, LL Wilson… - Frontiers in …, 2019 - europepmc.org
Abstract Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception
without the liabilities of opioids, offering a promising therapeutic target to treat pain. The …
without the liabilities of opioids, offering a promising therapeutic target to treat pain. The …
[引用][C] Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
TJ Cirino, SO Eans, JM Medina, LL Wilson… - Frontiers in …, 2019 - cir.nii.ac.jp
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel
Therapeutics Against Allodynia and Induced Pain | CiNii Research CiNii 国立情報学研究所 学術 …
Therapeutics Against Allodynia and Induced Pain | CiNii Research CiNii 国立情報学研究所 学術 …
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
TJ Cirino, SO Eans, JM Medina, LL Wilson… - Frontiers in …, 2019 - hero.epa.gov
Abstract Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception
without the liabilities of opioids, offering a promising therapeutic target to treat pain. The …
without the liabilities of opioids, offering a promising therapeutic target to treat pain. The …
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
TJ Cirino, SO Eans, JM Medina, LL Wilson… - Sigma …, 2020 - books.google.com
Chronic pain is the number one cause of adult disability in the United States. According to
the National Institutes of Health, an estimated 20 million individuals suffer from some form of …
the National Institutes of Health, an estimated 20 million individuals suffer from some form of …
[PDF][PDF] Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
TJ Cirino, SO Eans, JM Medina, LL Wilson… - Frontiers in …, 2019 - iris.unict.it
Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception without
the liabilities of opioids, offering a promising therapeutic target to treat pain. The purpose of …
the liabilities of opioids, offering a promising therapeutic target to treat pain. The purpose of …
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
TJ Cirino, SO Eans, JM Medina… - Frontiers in …, 2019 - pubmed.ncbi.nlm.nih.gov
Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception without
the liabilities of opioids, offering a promising therapeutic target to treat pain. The purpose of …
the liabilities of opioids, offering a promising therapeutic target to treat pain. The purpose of …
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain.
TJ Cirino, SO Eans, JM Medina, LL Wilson… - Frontiers in …, 2019 - europepmc.org
Abstract Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception
without the liabilities of opioids, offering a promising therapeutic target to treat pain. The …
without the liabilities of opioids, offering a promising therapeutic target to treat pain. The …
[PDF][PDF] Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
TJ Cirino, SO Eans, JM Medina, LL Wilson… - Frontiers in …, 2019 - iris.unict.it
Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception without
the liabilities of opioids, offering a promising therapeutic target to treat pain. The purpose of …
the liabilities of opioids, offering a promising therapeutic target to treat pain. The purpose of …